Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany

Abstract

The relatively high average annual costs per patient indicate need for efficient control of psoriasis. This cost-of-illness study provides basic data for further decision making, including economic assessment of innovative therapies for psoriasis.